


# Brightening the Future of Immunology with New Frontiers in Science

We are a team of passionate scientists, visionary entrepreneurs, and innovators who are driven by a shared vision of a future where immune-mediated diseases no longer hold patients and their loved ones back.



## High unmet need for immune-mediated diseases



*“Immune-mediated diseases can manifest in various ways and present unique challenges to patients and their families, from the **muscle weakness and skin inflammation of dermatomyositis** to the painful and chronic **gut inflammation of ulcerative colitis** and the **joint pain of rheumatoid arthritis.**”*

Daniele D'Ambrosio  
Head of Immunology

## Two decades of immunology research and development

With over 20 years of experience, we have built a vast bank of proprietary knowledge on disease biology. Our research has yielded a wealth of data, insights and results, including the approval of our first medicine.


### 2020 — APPROVAL OF OUR FIRST MEDICINE FILGOTINIB

Marketed today as Filgotinib in Europe and Japan in 2 indications: rheumatoid arthritis (RA) and ulcerative colitis (UC).

We are expanding the impact of Filgotinib with potential new indications.

## Our focus in immunology


By exploring new frontiers in science and technology, we strive to deliver targeted treatments that enable patients and their families to live lives free from the constraints of immune-mediated conditions.



<sup>1</sup> He MM, Lo CH, Wang K, et al. Immune-Mediated Diseases Associated With Cancer Risks. JAMA Oncol. 2022;8(2):209-219  
<sup>2</sup> Non approved indications

# Rapidly advancing and expanding our immunology pipeline

Seeing the impact that our first commercial medicine has already had on patients has made us more passionate than ever about rapidly advancing and expanding our immunology pipeline. We aim to brighten the horizon of possibilities with multiple modes-of-action and drug modalities.



## Multiple modes-of-action

OUR SMALL MOLECULE PORTFOLIO IS TRIPLE IN NATURE



**JAK Program**  
Development of medicines to target Janus kinases (JAKs) to address the chronic inflammation.



**TYK Program**  
Development of precise medicines that target specific elements of the immune system, distinguishing them from current therapies that broadly suppress the immune system.



**SIK Program**  
Development of new medicines that inhibit SIK proteins to restore immune balance in immune-mediated diseases, which is different from existing therapies that mainly suppress the immune system.

## OUR CELL THERAPY PORTFOLIO IS EXPANDING — THE CD19 CAR-T PROGRAM

Evaluating CAR-T therapy for the treatment of refractory systemic lupus erythematosus and other chronic immune-mediated diseases.

Unique approach to CAR-T manufacturing at the point-of-care.

## Working hand in hand

We recognize the complexity of developing therapies for immunological diseases, and that's why we work hand in hand with patients, patient organizations, scientists, healthcare professionals, research institutions, academia, and other partners. Our collaborative approach allows us to drive innovation and accelerate progress toward life-changing treatments.

Let's work towards a brighter tomorrow  
at [glp.com/immunology](https://www.glp.com/immunology)

TOGETHER WE ARE  
LIVING INNOVATION